前往化源商城

COMPLEMENTC5 来源于人类血清

更新时间:2025-10-04 12:10:56

COMPLEMENTC5 来源于人类血清结构式
COMPLEMENTC5 来源于人类血清结构式
品牌特惠专场
常用名 COMPLEMENTC5 来源于人类血清 英文名 C5, HUMAN
CAS号 80295-53-0 分子量 N/A
密度 N/A 沸点 N/A
分子式 N/A 熔点 N/A
MSDS 美版 闪点 N/A

 COMPLEMENTC5 来源于人类血清名称

中文名 COMPLEMENTC5 来源于人类血清
英文名 C5, HUMAN

 COMPLEMENTC5 来源于人类血清物理化学性质

储存条件 −70°C

 COMPLEMENTC5 来源于人类血清安全信息

危害码 (欧洲) B
危险品运输编码 NONH for all modes of transport
WGK德国 3

 COMPLEMENTC5 来源于人类血清文献3

更多文献
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

N. Engl. J. Med. 350 , 552-559, (2004)

Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface protei...

Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.

Mini Rev. Med. Chem. 11 , 528-535, (2011)

Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evide...

The role of complement inhibition in PNH. Hillmen P.

Hematology Am. Soc. Hematol. Educ. Program 2008(1) , 116-123, (2008)

本网页内容来自不同专业数据源,如对内容有疑义,欢迎联系service1@chemsrc.com。
品牌现货直购
推荐供应商:

查看所有供应商和价格请点击:

COMPLEMENTC5 来源于人类血清生产厂家

COMPLEMENTC5 来源于人类血清价格

相关化合物: 更多...
COMPLEMENTC6 来源于人类血清
80295-56-3
COMPLEMENTC4 来源于人类血清
80295-48-3
COMPLEMENT C9 来源于人类血清
80295-59-6
COMPLEMENT C8 来源于人类血清
80295-58-5
VITRONECTIN 来源于人类血浆
83380-82-9
α1-抗胰凝乳蛋白酶
141176-92-3
人血浆提取蛋白C
42617-41-4
COMPLEMENT FACTOR H 来源于人类血浆
80295-65-4
COMPLEMENT FACTOR D 来源于人类血浆
37213-56-2
N-(2-(4-(4-(4-fluorophenyl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)cyclopentanecarboxamide
1021025-32-0
N-(2-(4-(azepan-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-2-cyclopentylacetamide
1021122-64-4
2-cyclopentyl-N-(2-(4-(4-(4-methoxyphenyl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)acetamide
1021060-99-0
N-(2-(4-(4-benzylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-2-cyclopentylacetamide
1021094-12-1
2-cyclopentyl-N-(2-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)acetamide
1021025-35-3
N-(2-(4-(4-benzylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-cyclohexylpropanamide
1021122-66-6
(1s,3s)-N-(2-(4-(piperidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)adamantane-1-carboxamide
1021094-14-3
(1s,3s)-N-(2-(4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)adamantane-1-carboxamide
1021025-38-6
N-{2-[4-(azepan-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl}adamantane-1-carboxamide
1021122-68-8
N-{2-[4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl}adamantane-1-carboxamide
1021061-04-0